Maze Therapeutics (NASDAQ:MAZE) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Maze Therapeutics (NASDAQ:MAZE) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other research analysts also recently weighed in on MAZE. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Price Performance

Shares of NASDAQ:MAZE opened at $27.95 on Friday. The company’s 50-day moving average is $27.88 and its 200 day moving average is $32.83. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a market capitalization of $1.55 billion, a P/E ratio of -11.09 and a beta of 2.22. Maze Therapeutics has a fifty-two week low of $12.81 and a fifty-two week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting the consensus estimate of ($0.76). On average, equities research analysts forecast that Maze Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This trade represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the sale, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 140,674 shares of company stock worth $3,904,707. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. TRV GP IV LLC purchased a new position in Maze Therapeutics in the 2nd quarter valued at approximately $133,502,907,000. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics during the second quarter worth $122,983,582,000. BlackRock Inc. purchased a new stake in shares of Maze Therapeutics during the second quarter worth $104,525,000. Jupiter Topco LLC bought a new position in shares of Maze Therapeutics in the second quarter worth $101,764,000. Finally, Janus Henderson Group PLC grew its position in shares of Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.